Paraneoplastic neurologic syndrome in ovarian carcinoma

Paraneoplastic neurologic syndrome in ovarian carcinoma Objectives: Paraneoplastic neurologic syndrome (PNS) is a rare entity in ovarian cancer. The objective of this study was to assess the incidence, clinicopathologic features, and survival outcomes of patients with ovarian, primary peritoneal, or fallopian tube cancer (OC) diagnosed with PNS.</P>Methods: We performed a retrospective review of all patients diagnosed with OC and PNS between 1995 and 2013. Characteristics of epithelial OC (EOC) with and without PNS diagnosed between 2003 and 2012 were also compared. Fisher's exact and Wilcoxon rank sum tests were used to compare categorical and continuous variables, respectively. Survival was estimated and compared using the product limit estimator of Kaplan–Meier and log-rank statistic.</P>Results: Of the 4552 OC patients, 15 (0.3%) were diagnosed with PNS, 47% prior to OC diagnosis, 33% during primary treatment, and 20% at recurrence. Sixty-seven percent (n = 10) were confirmed with onconeural antibodies, primarily anti-Yo (9/10, 90%). Among patients with PNS, median age was 59 years (range, 21–74 years). Tumor histology was predominantly serous (67%), mixed epithelial (13%), or immature teratoma (7%). PNS presented with muscle weakness (53%), ataxia (47%), confusion (33%), fatigue (27%), nystagmus (20%), multifocal neuropathy (13%), altered mental status (13%), and paresthesias (13%). Median duration of PNS symptoms was 18 months (range, 2–68 months). Treatments for PNS, given alone or in combination, included intravenous immunoglobulin (67%), corticosteroids (53%), plasmapheresis (47%), and chemotherapy (20%). Overall, only 33% of patients responded completely to PNS therapy. Sixty percent required greater than one line of therapy. If PNS symptoms were not resolve after first-line therapy, complete resolution of symptoms was unlikely. In the analysis of 563 EOC, compared to patients without PNS (n = 553), patients with PNS (n = 10) had worse performance status ( P = 0.005) and a trend toward higher median CA-125 levels at diagnosis (536 U/mL vs. 2580 U/mL, P = 0.08). There was no difference in OS between the two groups (34.9 vs. 59.5 months, P = 0.23).</P>Conclusions: In our population, PNS was an uncommon complication but was more commonly seen in EOC. In general, complete response to PNS therapy was low, with a significant number of patients experiencing persistence of symptoms after treatment. Patients with PNS had no difference in OS compared to patients without PNS.</P> http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Gynecologic Oncology Elsevier

Loading next page...
1 Page
 
/lp/elsevier/paraneoplastic-neurologic-syndrome-in-ovarian-carcinoma-nnMPppt238
Publisher
Elsevier
Copyright
Copyright © 2015 Elsevier Ltd
ISSN
0090-8258
eISSN
1095-6859
D.O.I.
10.1016/j.ygyno.2015.01.454
Publisher site
See Article on Publisher Site

Abstract

Objectives: Paraneoplastic neurologic syndrome (PNS) is a rare entity in ovarian cancer. The objective of this study was to assess the incidence, clinicopathologic features, and survival outcomes of patients with ovarian, primary peritoneal, or fallopian tube cancer (OC) diagnosed with PNS.</P>Methods: We performed a retrospective review of all patients diagnosed with OC and PNS between 1995 and 2013. Characteristics of epithelial OC (EOC) with and without PNS diagnosed between 2003 and 2012 were also compared. Fisher's exact and Wilcoxon rank sum tests were used to compare categorical and continuous variables, respectively. Survival was estimated and compared using the product limit estimator of Kaplan–Meier and log-rank statistic.</P>Results: Of the 4552 OC patients, 15 (0.3%) were diagnosed with PNS, 47% prior to OC diagnosis, 33% during primary treatment, and 20% at recurrence. Sixty-seven percent (n = 10) were confirmed with onconeural antibodies, primarily anti-Yo (9/10, 90%). Among patients with PNS, median age was 59 years (range, 21–74 years). Tumor histology was predominantly serous (67%), mixed epithelial (13%), or immature teratoma (7%). PNS presented with muscle weakness (53%), ataxia (47%), confusion (33%), fatigue (27%), nystagmus (20%), multifocal neuropathy (13%), altered mental status (13%), and paresthesias (13%). Median duration of PNS symptoms was 18 months (range, 2–68 months). Treatments for PNS, given alone or in combination, included intravenous immunoglobulin (67%), corticosteroids (53%), plasmapheresis (47%), and chemotherapy (20%). Overall, only 33% of patients responded completely to PNS therapy. Sixty percent required greater than one line of therapy. If PNS symptoms were not resolve after first-line therapy, complete resolution of symptoms was unlikely. In the analysis of 563 EOC, compared to patients without PNS (n = 553), patients with PNS (n = 10) had worse performance status ( P = 0.005) and a trend toward higher median CA-125 levels at diagnosis (536 U/mL vs. 2580 U/mL, P = 0.08). There was no difference in OS between the two groups (34.9 vs. 59.5 months, P = 0.23).</P>Conclusions: In our population, PNS was an uncommon complication but was more commonly seen in EOC. In general, complete response to PNS therapy was low, with a significant number of patients experiencing persistence of symptoms after treatment. Patients with PNS had no difference in OS compared to patients without PNS.</P>

Journal

Gynecologic OncologyElsevier

Published: Apr 1, 2015

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off